Israel Englander Y M Abs Therapeutics, Inc. Transaction History

Millennium Management LLC

$192 Billion
Q4 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 35,447 shares of YMAB stock, worth $219,771. This represents 0.0% of its overall portfolio holdings.

Number of Shares

35,447

Previous 71,586 50.48%

Holding current value

$219,771

Previous $939,000 70.5%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$7.76 - $15.69 $280,438 - $567,020	-36,139 Reduced 50.48%	35,447 $277,000
Q3 2024 Nov 14, 2024	SELL	$9.95 - $15.39 $2.77 Million - $4.28 Million	-278,198 Reduced 79.53%	71,586 $939,000
Q2 2024 Aug 14, 2024	BUY	$11.6 - $17.25 $779,902 - $1.16 Million	67,233 Added 23.79%	349,784 $4.23 Million
Q1 2024 May 15, 2024	BUY	$6.57 - $18.69 $1.72 Million - $4.89 Million	261,490 Added 1241.58%	282,551 $4.59 Million
Q4 2023 Feb 14, 2024	SELL	$4.88 - $7.42 $1.51 Million - $2.29 Million	-308,508 Reduced 93.61%	21,061 $143,000
Q2 2023 Aug 14, 2023	SELL	$5.68 - $10.34 $1.67 Million - $3.04 Million	-293,522 Reduced 47.11%	329,569 $2.24 Million
Q1 2023 May 15, 2023	SELL	$2.83 - $5.11 $1.43 Million - $2.58 Million	-505,611 Reduced 44.8%	623,091 $3.12 Million
Q4 2022 Feb 14, 2023	BUY	$3.0 - $15.17 $3.32 Million - $16.8 Million	1,105,069 Added 4675.96%	1,128,702 $5.51 Million
Q3 2022 Nov 14, 2022	SELL	$13.96 - $19.67 $811,690 - $1.14 Million	-58,144 Reduced 71.1%	23,633 $341,000
Q2 2022 Aug 15, 2022	BUY	$8.22 - $15.13 $672,206 - $1.24 Million	81,777 New	81,777 $1.24 Million
Q1 2022 May 16, 2022	SELL	$6.55 - $17.42 $82,615 - $219,718	-12,613 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$15.51 - $29.31 $195,627 - $369,687	12,613 New	12,613 $204,000
Q2 2021 Aug 16, 2021	SELL	$25.45 - $37.64 $7.25 Million - $10.7 Million	-284,888 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$29.16 - $51.96 $5.24 Million - $9.34 Million	179,831 Added 171.17%	284,888 $8.62 Million
Q4 2020 Feb 16, 2021	BUY	$37.86 - $54.26 $328,965 - $471,465	8,689 Added 9.02%	105,057 $5.2 Million
Q3 2020 Nov 16, 2020	SELL	$35.13 - $43.62 $293,405 - $364,314	-8,352 Reduced 7.98%	96,368 $3.7 Million
Q2 2020 Aug 14, 2020	SELL	$23.66 - $49.53 $938,189 - $1.96 Million	-39,653 Reduced 27.47%	104,720 $4.52 Million
Q1 2020 May 14, 2020	SELL	$14.39 - $35.8 $3.52 Million - $8.77 Million	-244,922 Reduced 62.91%	144,373 $3.77 Million
Q4 2019 Feb 14, 2020	BUY	$23.81 - $33.78 $4.87 Million - $6.91 Million	204,489 Added 110.65%	389,295 $12.2 Million
Q3 2019 Nov 14, 2019	SELL	$21.57 - $31.37 $4.7 Million - $6.83 Million	-217,687 Reduced 54.08%	184,806 $4.82 Million
Q2 2019 Aug 14, 2019	BUY	$19.51 - $28.31 $2.28 Million - $3.31 Million	116,967 Added 40.97%	402,493 $9.21 Million
Q1 2019 May 14, 2019	SELL	$18.21 - $26.21 $1.85 Million - $2.66 Million	-101,393 Reduced 26.21%	285,526 $7.48 Million
Q4 2018 Feb 14, 2019	BUY	$15.41 - $28.92 $1.03 Million - $1.94 Million	67,013 Added 20.95%	386,919 $7.87 Million
Q3 2018 Nov 14, 2018	BUY	$24.0 - $26.97 $7.68 Million - $8.63 Million	319,906 New	319,906 $8.5 Million

About Y-mAbs Therapeutics, Inc.

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $271M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

More about YMAB

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account